Jazz Pharmaceuticals projected its 2026 revenue to reach between $4.60 billion and $4.75 billion while awaiting an August 25 FDA decision on its drug candidate zanidatamab. In August, the company announced the acquisition of Actio Biosciences for $820 million, in a deal potentially worth up to $1.32 billion. This strategic move centers on Actio's lead drug, ABS-1230, which targets rare KCNT1+ epilepsy.
The $820 million acquisition focuses on the lead drug ABS-1230 to strengthen Jazz's rare disease and epilepsy portfolio.
Read the full storyJazz Pharmaceuticals announced a deal to buy Actio Biosciences for up to $1.32 billion to add an experimental treatment for rare epilepsy.
The company forecasts revenue up to $4.75B by 2026 as it nears a critical FDA decision date for its cancer drug zanidatamab.